Your Article Summary
See Latest ArticlesTransdermal Nitroglycerin Therapy May Not Prevent Early Postmenopausal Bone Loss
Journal of Clinical Endocrinology and Metabolism, 07/01/09
Wimalawansa SJ et al. - BMD changes did not substantially differ between postmenopausal women who received the dose of nitroglycerin tested, in comparison to a placebo. Once-daily dosing with 22.5 mg of transdermal-administered nitroglycerin was not effective (compliance adjusted dose was -16 mg/day).
Sunil J. Wimalawansam, MD, PhD, MBA, 08/02/09
| This single center, three-year double-blind, randomized, clinical study in 188 early postmenopausal subjects, half received 22.5 mg of transdermal nitroglycerin (average dose ~16 mg/day) plus calcium plus vitamin D, while the control group received a placebo ointment, calcium and vitamin D. The primary endpoint, the lumbar spine BMD did not differ significant; under dosing of subjects was the primary reason for this. Taken together with other studies, we believe that higher dosages would not only preserve BMD, but may also improve fracture rates. If this is proven the case, nitric oxide donors are likely to be the most cost-effective therapy for prevention and treatment of osteoporosis. Hence, new studies are warranted in this fires of research. |
Related Articles
Intensity and timing of physical activity in relation to postmenopausal breast cancer risk: the prospective NIH-AARP Diet and Health Study
BMC Cancer, 10/05/09
Relevance Score: 90%
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Therapeutics and Clinical Risk Management, 10/16/09
Relevance Score: 89%
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Relevance Score: 89%
Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09
Relevance Score: 88%
Testosterone and biological characteristics of breast cancers in postmenopausal women
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09
Relevance Score: 88%
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial
BMC Infectious Diseases, 12/03/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09